The Spin-Off Arbitrage: When Medical Giants Shed Weight, Hidden Value Emerges

Executive Summary

Three seasoned value managers have identified a compelling arbitrage opportunity hiding in plain sight within the medical technology sector. Becton Dickinson's pending reverse Morris Trust transaction with Waters Corporation represents a textbook case of market inefficiency, where a $18.8 billion divestiture is trading at a massive discount to its component parts. The deal, expected to close by Q1 2026, will hand BDX shareholders approximately $65 per share in cash and Waters stock while leaving the remaining medical device business trading at less than 10 times forward earnings. This creates a rare combination of immediate value realization and a deeply undervalued stub equity. The thesis gains additional credibility from BDX's commitment to aggressive share repurchases using the $4 billion cash windfall, effectively creating a self-reinforcing value catalyst. Meanwhile, smaller opportunities like BK Technologies demonstrate how exceptional management can transform niche oligopolies into growth engines, with CEO John Suzuki expanding beyond wildland fire radios into the broader first responder market at gross margins exceeding 50%. The convergence of these ideas suggests sophisticated investors are finding alpha in overlooked corporate actions and management-driven transformations, even as broader markets trade at historically expensive valuations.

Key Insights